Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
August 18 2020 - 09:00AM
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that it has executed the definitive
supply agreement provided for in the previously announced binding
term sheet agreement with the Israeli Ministry of Health, to supply
COVID-19 STARR™ mRNA vaccine candidate (ARCT-021). Delivery to
Israel of doses of Arcturus’ COVID-19 vaccine candidate is
contingent upon achievement of near term clinical and regulatory
milestones.
“We are pleased to have executed the definitive
supply agreement with the Israeli Ministry of Health. Arcturus is
honored to play a key role in Israel’s COVID-19 vaccination
strategy. As indicated in a recent press conference on July
23rd, led by Prime Minister Netanyahu, this is considered a
significant deal to the government of Israel, providing them rights
and access to ARCT-021 and a path to potentially vaccinate a
substantial portion of their citizens against coronavirus,” said
Joseph Payne, President & CEO of Arcturus. “We value the
Israeli Ministry of Health’s commitment to our differentiating
STARR™ mRNA vaccine candidate and we look forward to advancing the
development of ARCT-021.”
Israel is the second country, in addition to
Singapore, to reserve supply of the ARCT-021 vaccine. Arcturus is
in active discussions with certain government entities in major
markets and other parts of the world. With the Company’s
manufacturing partners, Arcturus is in the process of manufacturing
millions of doses in 2020 and positioned to supply hundreds of
millions of doses annually thereafter.
For more information about rights and access to
Arcturus’ COVID-19 vaccine candidate, ARCT-021, please contact
Arcturus at Vax@ArcturusRx.com.
About STARR™ TechnologyThe
STARR™ Technology platform combines self-replicating RNA with
LUNAR®, a leading nanoparticle delivery system, into a single
solution to produce proteins inside the human body. The
versatility of the STARR™ Technology affords its ability upon
delivery into the cell to generate a protective immune response or
drive therapeutic protein expression to potentially prevent against
or treat a variety of diseases. The self-replicating RNA-based
therapeutic vaccine triggers rapid and prolonged antigen expression
within host cells resulting in protective immunity against
infectious pathogens. This combination of the LUNAR® and STARR™
technology is expected to provide lower dose requirements due to
superior immune response, sustained protein expression compared to
non-self-replicating RNA-based vaccines and potentially enable us
to produce vaccines more quickly and simply.
About Arcturus
TherapeuticsFounded in 2013 and based in San Diego,
California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a
clinical-stage mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology and (iii) mRNA drug substance along with drug product
manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic and vaccine candidates includes self-replicating mRNA
vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other
programs to potentially treat Ornithine Transcarbamylase (OTC)
Deficiency, Cystic Fibrosis, Cardiovascular Disease along with
partnered programs including Glycogen Storage Disease Type 3,
Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH).
Arcturus’ versatile RNA therapeutics platforms can be applied
toward multiple types of nucleic acid medicines including messenger
RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA,
DNA, and gene editing therapeutics. Arcturus’ technologies are
covered by its extensive patent portfolio (192 patents and patent
applications, issued in the U.S., Europe, Japan, China and other
countries). Arcturus’ commitment to the development of novel RNA
therapeutics has led to collaborations with Janssen
Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies
of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda
Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics
Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more
information visit www.ArcturusRx.com.
Forward Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Any statements, other than statements of historical fact included
in this press release, including those regarding the Company’s
efforts to develop a vaccine against COVID-19, and therapeutic
potential thereof, based on the Company’s mRNA therapeutics, the
ability of the Company to scale up manufacturing of vaccine doses,
regulatory approval of the vaccine against COVID-19, the potential
supply of the vaccine to government entities in major markets and
other parts of the world and the impact of general business and
economic conditions are forward-looking statements. Arcturus may
not actually achieve the plans, carry out the intentions or meet
the expectations or projections disclosed in any forward-looking
statements such as the foregoing and you should not place undue
reliance on such forward-looking statements. Such statements are
based on management’s current expectations and involve risks and
uncertainties, including those discussed under the heading "Risk
Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal
year ended December 31, 2019, filed with the SEC on March 16, 2020
and in subsequent filings with, or submissions to, the SEC. No
assurances can be given that any results reported in pre-clinical
studies can be replicated in further studies or in human beings, or
that a vaccine can or will ever be developed or approved using the
Company’s technology. A more fulsome description of the definitive
supply agreement will be included with the current report on Form
8-K to be filed by the Company with the SEC. Except as
otherwise required by law, Arcturus disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
IR and Media ContactsArcturus TherapeuticsNeda
Safarzadeh (858) 900-2682 IR@ArcturusRx.com
Kendall Investor RelationsCarlo Tanzi, Ph.D. (617)
914-0008 ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Mar 2023 to Mar 2024